Literature DB >> 17193252

Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins.

Angelo Carotti1, Cosimo Altomare, Marco Catto, Carmela Gnerre, Luciana Summo, Agostino De Marco, Sarah Rose, Peter Jenner, Bernard Testa.   

Abstract

A series of coumarin derivatives (1-22), bearing at the 7-position ether, ketone, ester, carbamate, or amide functions of varying size and lipophilicity, were synthesized and investigated for their in vitro monoamine oxidase-A and -B (MAO-A and -B) inhibitory activities. Most of the compounds acted preferentially as MAO-B inhibitors, with IC(50) values in the micromolar to low-nanomolar range. A structure-activity-relationship (SAR) study highlighted lipophilicity as an important property modulating the MAO-B inhibition potency of 7-substituted coumarins, as shown by a linear correlation (n=20, r(2)=0.72) between pIC(50) and calculated log P values. The stability of ester-containing coumarin derivatives in rat plasma provided information on factors that either favor (lipophilicity) or decrease (steric hindrance) esterase-catalyzed hydrolysis. Two compounds (14 and 22) were selected to investigate how lipophilicity and enzymatic stability may affect in vivo MAO activities, as assayed ex vivo in rat. The most-potent and -selective MAO-B inhibitor 22 (=7-[(3,4-difluorobenzyl)oxy]-3,4-dimethyl-1-benzopyran-2(2H)-one) within the examined series significantly inhibited (>60%) ex vivo rat-liver and striatal MAO-B activities 1 h after intraperitoneal administration of high doses (100 and 300 mumol kg(-1)), revealing its ability to cross the blood-brain barrier. At the same doses, liver and striatum MAO-A was less inhibited in vivo, somehow reflecting MAO-B selectivity, as assessed in vitro. In contrast, the metabolically less stable derivative 14, bearing an isopropyl ester in the lateral chain, had a weak effect on hepatic MAO-B activity in vivo, and none on striatal MAO-B, but, surprisingly, displayed inhibitory effects on MAO-A in both peripheral and brain tissues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17193252     DOI: 10.1002/cbdv.200690017

Source DB:  PubMed          Journal:  Chem Biodivers        ISSN: 1612-1872            Impact factor:   2.408


  5 in total

1.  Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and In Silico Studies.

Authors:  Guillermo Moya-Alvarado; Osvaldo Yañez; Nicole Morales; Angélica González-González; Carlos Areche; Marco Tulio Núñez; Angélica Fierro; Olimpo García-Beltrán
Journal:  Molecules       Date:  2021-04-22       Impact factor: 4.411

2.  Dual-target anti-Alzheimer's disease agents with both iron ion chelating and monoamine oxidase-B inhibitory activity.

Authors:  Zhisheng Mi; Bing Gan; Sihang Yu; Jianan Guo; Changjun Zhang; Xiaoying Jiang; Tao Zhou; Jing Su; Renren Bai; Yuanyuan Xie
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

3.  Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes.

Authors:  Jason K Cullen; Glen M Boyle; Pei-Yi Yap; Stefan Elmlinger; Jacinta L Simmons; Natasa Broit; Jenny Johns; Blake Ferguson; Lidia A Maslovskaya; Andrei I Savchenko; Paul Malek Mirzayans; Achim Porzelle; Paul V Bernhardt; Victoria A Gordon; Paul W Reddell; Alberto Pagani; Giovanni Appendino; Peter G Parsons; Craig M Williams
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

Review 4.  Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds.

Authors:  Angela Stefanachi; Francesco Leonetti; Leonardo Pisani; Marco Catto; Angelo Carotti
Journal:  Molecules       Date:  2018-01-27       Impact factor: 4.411

5.  Synthesis and Biological Evaluation of Dantrolene-Like Hydrazide and Hydrazone Analogues as Multitarget Agents for Neurodegenerative Diseases.

Authors:  Isabella Bolognino; Nicola Giangregorio; Annamaria Tonazzi; Antón L Martínez; Cosimo D Altomare; María I Loza; Sara Sablone; Saverio Cellamare; Marco Catto
Journal:  ChemMedChem       Date:  2021-06-22       Impact factor: 3.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.